SS
ACRS icon

SBI Securities’s Aclaris Therapeutics ACRS Stock Holding History

SBI Securities’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354 Hold
67
– – ﹤0.01% 3153
2026
Q1 		$251 Sell
67
-12
-15% -$40 ﹤0.01% 3132
2025
Q4 		$238 Sell
79
-160
-67% -$404 ﹤0.01% 3154
2025
Q3 		$454 Sell
239
-28
-10% -$49 ﹤0.01% 3009
2025
Q2 		$379 Buy
267
+200
+299% +$271 ﹤0.01% 3075
2025
Q1 		$103 Buy
67
+1
+2% +$2 ﹤0.01% 3430
2024
Q4 		$164 Buy
+66
New +$164 ﹤0.01% 3311

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

SBI Securities's ACRS Position: Q2 2026 in Review

SBI Securities held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 67 shares worth $354. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

SBI Securities first reported a position in ACRS in Q4 2024 and has held it in 7 quarters since. The position peaked at $454 in Q3 2025. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • SBI Securities held 67 shares of Aclaris Therapeutics worth $354 as of Q2 2026.
  • SBI Securities left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3153 holding.
  • SBI Securities first reported a position in Aclaris Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Aclaris Therapeutics position peaked at $454 in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.